Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010294 | 0.77 | ALDH1A1 (0.34) | EPHX2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31010265 | 0.74 | EPHX2 (0.42) | EPHX2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21166107 | 0.73 | — | — | |
| SCHEMBL21165962 | 0.69 | — | — | |
| SCHEMBL29961764 | 0.69 | ALDH1A1 (0.37) | EPHX2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21166146 | 0.67 | NPC1 (0.60) | EPHX2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL255119 | 0.66 | — | — | |
| SCHEMBL21945129 | 0.65 | KCNH2 (0.37) | NPC1RAB9ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL31010357 | 0.65 | EPHX2 (0.37) | EPHX2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL173859 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | GRUENENTHAL GMBH (DE) | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252473-A1 | Sulfoximines as inhibitors of NaV1.8 | SCN8A, SCN10A, SCN7A | EPHX2 3174/4885NPC1 4661/4885RAB9A 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.